Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Trial details
- Registry ID
- NCT05571059
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ifetroban
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059 | Cumberland Pharmaceuticals | Phase 2 | Recruiting | 2028-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |